# Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects

> **NCT04543370** · PHASE1 · COMPLETED · sponsor: **Catabasis Pharmaceuticals** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Edasalonexent 2000 mg TID
- **DRUG:** Midazolam 2 MG/ML
- **DRUG:** Deflazacort 36Mg Tab

## Key facts

- **NCT ID:** NCT04543370
- **Lead sponsor:** Catabasis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-08
- **Primary completion:** 2020-09-06
- **Final completion:** 2020-10-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543370, "Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04543370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*